Filing Analysis
Assertio Holdings, Inc. has been acquired by Zydus Worldwide DMCC. The company has become a wholly owned subsidiary of Zydus following a tender offer and a subsequent merger under Section 251(h) of the DGCL.
🚩 Red Flags
- Delisting of common stock from Nasdaq.
- Triggering of 'Fundamental Change' and 'Make-Whole' provisions on $40M of convertible debt, creating an immediate cash repurchase obligation.
📋 Key Facts
- Acquisition price set at $23.50 per share in cash.
- Tender offer expired June 15, 2026, with 4,286,488 shares (approx. 66.32%) validly tendered.
- Merger consummated on June 16, 2026, making the company a wholly owned subsidiary of Zydus Worldwide DMCC.
- Company requested Nasdaq to halt trading and delist shares effective before the opening of trading on June 16, 2026.
- Outstanding 6.50% Convertible Senior Notes due 2027 ($40M principal) triggered a 'Fundamental Change' and 'Make-Whole Fundamental Change' on June 16, 2026.
- Note holders now have the right to require the company to repurchase notes at 100% of principal plus accrued interest.
Assertio Holdings, Inc. (ASRT) entered into an Agreement and Plan of Merger on May 13, 2026 with Zydus Worldwide DMCC (UAE-based parent entity), pursuant to which Zydus will acquire all outstanding ASRT common shares via a cash tender offer at $23.50 per share. Following the tender offer, Purchaser (Zara Merger Sub Inc.) will merge into Assertio, making it a wholly owned subsidiary of Zydus. The tender offer was set to commence on May 18, 2026.
🚩 Red Flags
- Merger closing is contingent on regulatory approvals and tender conditions — deal failure risk remains
- Convertible Notes (6.50% due 2027) triggered Fundamental Change provisions, creating potential cash repurchase obligations that could complicate deal economics
- Parent is a UAE-incorporated entity (Zydus Worldwide DMCC), introducing cross-border regulatory and geopolitical closing risk
- Parent waived the Note Offer requirement, removing a key debt management mechanism originally contemplated in the Merger Agreement — may signal complexity in debt handling
- Potential for competing offers or shareholder litigation as noted in forward-looking risk factors
- Employee retention and business disruption risks cited during pendency of the transaction
📋 Key Facts
- Merger Agreement signed May 13, 2026 between Assertio Holdings and Zydus Worldwide DMCC (UAE)
- Cash tender offer price of $23.50 per share of Common Stock
- Acquirer entity: Zydus Worldwide DMCC; Purchaser subsidiary: Zara Merger Sub Inc. (Delaware); Guarantor: Zydus Pharmaceuticals (USA) Inc. (New Jersey)
- Tender offer (Offer) commenced May 18, 2026
- Company has outstanding 6.50% Convertible Senior Notes due 2027 (Convertible Notes)
- Merger constitutes a 'Fundamental Change' and 'Make-Whole Fundamental Change' under the Convertible Notes Indenture
- Convertible Note holders have right to require repurchase at 100% of principal plus accrued interest, OR convert at an increased rate during Make-Whole Fundamental Change Period
- Parent waived the requirement for Assertio to commence a Note Offer on May 18, 2026
- Filing checked as 'Pre-commencement communications pursuant to Rule 13e-4(c)' — indicating issuer tender offer involvement
- Schedule TO to be filed by Parent/Purchaser; Schedule 14D-9 (Solicitation/Recommendation Statement) to be filed by Assertio
- Signed by Sam Schlessinger, EVP and General Counsel
Assertio Holdings (ASRT) has entered into a definitive merger agreement to be acquired by Zydus Worldwide DMCC for $23.50 per share in cash via a tender offer. This transaction follows Assertio's termination of a previous merger agreement with Garda Therapeutics after determining the Zydus proposal was superior.
🚩 Red Flags
- The merger is subject to a strict 'Closing Net Cash' requirement of $95 million, which may be a risk if operations consume cash before closing.
- The company incurred a termination fee obligation to Garda Therapeutics (amount not specified in text but referenced as a reimbursement requirement).
📋 Key Facts
- Zydus Worldwide DMCC will acquire Assertio for $23.50 per share in an all-cash tender offer.
- The deal is contingent on a minimum tender of at least 50% plus one share of outstanding common stock.
- A specific closing condition requires Assertio to have at least $95,000,000 in 'Closing Net Cash'.
- Assertio terminated a prior merger agreement with Garda Therapeutics, Inc. dated May 1, 2026, to accept this superior proposal.
- Assertio must pay a termination fee of $6,263,180 to Zydus if the deal is terminated under specific circumstances, plus reimburse the Garda termination fee.
- The company will conduct a note offer for its $40,000,000 aggregate principal amount of 6.50% Convertible Notes due 2027.
Assertio Holdings and Garda Therapeutics have mutually agreed to extend the deadline for commencing a tender offer to purchase all outstanding shares of Assertio common stock. The commencement deadline has been moved to May 14, 2026, in connection with the merger agreement dated May 1, 2026.
🚩 Red Flags
- Delay in the commencement of a previously announced tender offer, which can sometimes indicate execution risks or pending regulatory/administrative hurdles.
📋 Key Facts
- The Company entered into an Amended and Restated Agreement and Plan of Merger on May 1, 2026.
- The parties involved are Assertio Holdings, Inc., Garda Therapeutics, Inc., and Audi Merger Sub, Inc.
- The deadline to commence the tender offer was extended from the original date to May 14, 2026.
- The tender offer is intended to purchase all outstanding shares of the Company's common stock.
Assertio Holdings, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on May 5, 2026. Stockholders approved an amendment to the company's 2014 Omnibus Incentive Plan to increase the share pool by 400,000 shares and ratified the appointment of Grant Thornton LLP as the independent auditor.
📋 Key Facts
- Stockholders approved an increase of 400,000 shares to the Amended and Restated 2014 Omnibus Incentive Plan.
- Six director nominees (Heather L. Mason, Sravan K. Emany, Sigurd C. Kirk, William T. McKee, Mark L. Reisenauer, and David M. Stark) were elected to serve until the 2027 Annual Meeting.
- The advisory vote on executive compensation (Say-on-Pay) was approved with 1,739,652 votes for and 451,308 against.
- Grant Thornton LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 3,577,437 votes in favor.
Assertio Holdings announced a mutual agreement with Garda Therapeutics to extend the commencement deadline for a tender offer to purchase all outstanding ASRT shares. The new deadline is set for May 8, 2026, following an Amended and Restated Agreement and Plan of Merger.
🚩 Red Flags
- Delay in the commencement of the tender offer, which can occasionally signal underlying execution risks or financing hurdles.
📋 Key Facts
- The Company reached a mutual agreement with Garda Therapeutics, Inc. and Audi Merger Sub, Inc. to extend the tender offer deadline.
- The new deadline for commencing the tender offer is May 8, 2026.
- The extension relates to an Amended and Restated Agreement and Plan of Merger dated May 1, 2026.
- The tender offer involves the purchase of all outstanding shares of Assertio common stock.
Assertio Holdings entered into an amended merger agreement with Garda Therapeutics, increasing the cash acquisition price to $21.80 per share from the previous $18.00 plus a contingent value right (CVR). The transaction is structured as a tender offer for all outstanding shares, followed by a merger to make Assertio a wholly owned subsidiary of Garda.
🚩 Red Flags
- The deal is contingent on the company maintaining a high cash balance of at least $95,000,000 at closing.
- Removal of the CVR suggests that potential future milestone payments have been forfeited for immediate cash.
📋 Key Facts
- Offer price increased to $21.80 per share in cash, representing a significant increase from the original $18.00 cash component.
- The non-tradeable Contingent Value Right (CVR) from the original April 8, 2026 agreement has been removed in favor of the higher cash price.
- The deal is supported by $130 million in debt financing from Colbeck Capital Management and $22.2 million in equity commitments from Joseph M. Limber and Brett K.E. Lund.
- A minimum 'Closing Net Cash' condition of $95,000,000 is required for the deal to close.
- A termination fee of $5,810,000 is payable by either party under specific circumstances, including a 'Superior Proposal' or breach of contract.
Assertio Holdings, Inc. has mutually agreed with Garda Therapeutics to extend the commencement date of the tender offer for all outstanding ASRT shares to May 4, 2026. This extension pertains to the merger agreement originally entered into on April 8, 2026.
🚩 Red Flags
- Delay in the commencement of the tender offer process
📋 Key Facts
- Mutual agreement to extend the tender offer commencement deadline to May 4, 2026
- Merger agreement originally dated April 8, 2026, involving Garda Therapeutics, Inc. and Audi Merger Sub, Inc.
- The tender offer is for all outstanding shares of Assertio common stock
- The announcement was made via a press release on April 29, 2026
Assertio Holdings announced that Garda Therapeutics will launch a tender offer on April 29, 2026, to purchase all outstanding shares of the company. The offer follows the expiration of a 20-day "window-shop" period established in the April 8, 2026, Merger Agreement.
📋 Key Facts
- Garda Therapeutics to commence tender offer for all outstanding shares on April 29, 2026.
- The offer follows a Merger Agreement dated April 8, 2026.
- A 20-day "window-shop" period expires on April 28, 2026.
- The acquisition is being executed through Audi Merger Sub, Inc., a wholly owned subsidiary of Garda.
Assertio Holdings completed the sale of its INDOCIN, SPRIX, SYMPAZAN, CAMBIA, ZIPSOR, and OTREXUP product franchises to Cosette Pharmaceuticals for $35 million in upfront cash. The agreement includes significant contingent milestone payments totaling over $35 million and the assumption of manufacturing and clinical liabilities by the buyer.
🚩 Red Flags
- Divestiture of multiple core revenue-generating product lines (including INDOCIN and SYMPAZAN) significantly alters the company's fundamental business model.
- The sale of 'recently decommercialized' assets like OTREXUP may indicate previous operational struggles with the portfolio.
📋 Key Facts
- Upfront cash consideration of $35,000,000 received on April 8, 2026.
- Potential for $32,000,000 in aggregate net sales-based milestone payments for SYMPAZAN, INDOCIN, and OTREXUP.
- SPRIX-specific earn-outs include a $1,000,000 quality milestone, 8% gross profit sharing through 2027, and a $2,000,000 sales-based milestone.
- Cosette Pharmaceuticals assumed liabilities related to manufacturing, supply, post-market commitments, and clinical development costs.
- The sale includes the recently decommercialized OTREXUP franchise.
Assertio Holdings, Inc. has entered into an Agreement and Plan of Merger to be acquired by Garda Therapeutics, Inc. via a cash tender offer of $18.00 per share plus one Contingent Value Right (CVR) per share.
📋 Key Facts
- Acquisition price is $18.00 per share in cash (Base Purchase Price) plus one CVR per share.
- The transaction is structured as a cash tender offer followed by a merger under Section 251(h) of the Delaware General Corporation Law.
- Purchaser must commence the offer within 10 business days of the agreement (signed April 8, 2026).
- Closing is subject to the condition that the Company has Closing Net Cash of at least $115,000,000.
- The offer requires a minimum tender of one share more than 50% of outstanding common stock.
- Termination fee is $4,800,000, reducible to $1,750,000 if terminated for a Superior Proposal from a 'Qualified Bidder' during the Window Shop period.
Assertio Holdings has entered into a definitive agreement to be acquired by Garda Therapeutics for $18.00 per share in cash plus one contingent value right (CVR). The transaction is structured as a cash tender offer followed by a merger, with an expected outside date of June 21, 2026.
🚩 Red Flags
- The transaction is contingent on the company maintaining a minimum 'Closing Net Cash' of $115,000,000, which could be a risk if operational costs or liabilities increase before closing.
- The specific terms and triggers for the Contingent Value Right (CVR) payments are not detailed in the main text, creating uncertainty about the total eventual payout.
📋 Key Facts
- Acquisition price is $18.00 per share in cash plus one CVR representing potential future cash payments.
- The buyer is Garda Therapeutics, Inc., through its subsidiary Audi Merger Sub, Inc.
- The deal is not subject to a financing condition, meaning the buyer has committed funds.
- A closing condition requires Assertio to have at least $115,000,000 in 'Closing Net Cash'.
- The agreement includes a 'Window Shop' period allowing for a reduced termination fee of $1.75 million if a superior proposal is found; otherwise, the fee is $4.8 million.
- The Board of Directors unanimously recommended that stockholders accept the offer.
Assertio Holdings, Inc. announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The announcement was made via a press release on March 16, 2026, and filed under Item 2.02.
📋 Key Facts
- The filing date is March 16, 2026.
- The report covers the fiscal year and fourth quarter ended December 31, 2025.
- The information was disclosed under Item 2.02 (Results of Operations and Financial Condition).
- The report was signed by CEO Mark L. Reisenauer.